Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Confo, Roche collaborate on neurological therapeutics
February 2018
SHARING OPTIONS:

GHENT, Belgium—Drug discovery company Confo Therapeutics recently announced the beginning of a research collaboration and license agreement with Roche to discover, develop and commercialize novel small-molecule agonists of an undisclosed G-protein coupled receptor for treating neurological and developmental disorders. Per the agreement, Roche will have exclusive rights to any compounds resulting from this agreement, and will be responsible for the development, manufacturing and commercialization of said compounds. Roche will pay Confo €6 million (approximately $7.4 million) in an upfront payment, preclinical milestones and research funding over the first 30 months of the collaboration, with the potential for Confo to receive up to €81.5 million (approximately $99.9 million) if development, regulatory and commercial milestones are met. Confo is also eligible to receive tiered royalties on the annual net sales of any products generated by this collaboration.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.